[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "New treatment for depression", "description": "Boom in psychedelic therapies?\n\nhttps://www.telegraph.co.uk/news/2022/08/20/magic-mushrooms-set-become-uks-ultimate-weapon-against-depression/\n\nhttps://www.theguardian.com/science/2022/apr/12/psilocybin-depression-brain-break-out-of-a-rut-magic-mushrooms\n\nShort-acting drugs, psychedelic experience, two-hour therapy session.\n\nResetting brain networks\n\nHelping to end ingrained negative patterns of thought, \n\nand making patients far more receptive to therapy.\n\nSmall Pharma\n\nhttps://smallpharma.com\n\nLeading the world\u2019s first regulated clinical trial,\n\nDMT (dimethyltryptamine) with psychotherapy for major depressive disorder.\n\nPhase one done on healthy volunteers\n\nNext few months, reports from 42 patients\n\nDr Carol Routledge, chief medical and scientific officer\n\nWe think that this treatment will really get to the root cause, rather than just dampening symptoms\n\nAlmost immediate benefits\n\nBased on initial data that we already have, and other companies have, there\u2019s going to be a fairly immediate impact\n\nIn terms of the psychedelic experience, we\u2019re talking about 20 minutes, \n\nand then the integration therapy afterwards,\n\nwe expect the antidepressant activity to be extremely durable \u2026 to last maybe three, four or five months\n\nImaging data\n\nPsychedelics work on the brain networks\n\nMaking neural connections more flexible to brain plasticity\n\nYou can reset those networks in the brain, and then that leaves the brain much more receptive to therapy, which is why we bring it in straight afterwards\n\nMedicines and Healthcare products Regulatory Agency (MHRA)\n\nInnovative Licensing and Access Pathway (ILAP)\n\nBrings organisations together\n\nSpeed up the time getting meds to patients\n\nOther companies testing MDMA\n\n3,4-Methylenedioxymethamphetamine\n\nTherapy for post-traumatic stress disorder (PTSD)\n\nPsilocybin, (Clerkenwell Health)\n\nDepression\n\nSmoking\n\nTerminal illness\n\nPsychedelic experience\n\nOut-of-body sensations\n\nVisual or aural hallucinations\n\nPsilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls\n\nhttps://www.nature.com/articles/s41598-022-14512-3#Tab2\n\nUniversity of British Columbia, Vancouver, July, 2022\n\nPsilocybin microdosing\n\nRepeated self-administration of mushrooms containing psilocybin,\n\nat doses small enough to not impact regular functioning. \n\n3\u20135 times per week, of 0.1 to 0.3 g of dried mushrooms\n\nNaturalistic, observational design\n\nStudy approved, University of British Columbia Research Ethics Board (H19-03051)\n\nPsilocybin microdosers (n\u2009=\u2009953)\n\nNon-microdosing comparators (n\u2009=\u2009180)\n\nFor approximately 30 days\n\nIdentified small- to medium-sized improvements in mood and mental health,\n\nthat were generally consistent across gender, age and presence of mental health concerns\n\nImproved psychomotor performance in older adults.\n\nDepression, Anxiety and Stress Scale\n\nhttps://proceduresonline.com/trixcms2/media/11957/depression-anxiety-and-stress-scale-dass21.pdf\n\nAdults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers\n\nhttps://www.nature.com/articles/s41598-021-01811-4\n\nLarge international sample of adults\n\nmicrodosers (n\u2009=\u20094050) \n\nnon-microdosers (n\u2009=\u20094653)\n\nPsilocybin, 85% of microdosers, (LSD, 11%)\n\nmicrodosers exhibited lower levels of depression, anxiety, and stress across gender\n\nmicrodosers were less likely to use alcohol regularly and were more likely to abstain from alcohol entirely\n\nmicrodosers were more likely to abstain from the use of nicotine\n\nPsilocybin, in 10mg or 25mg doses, has no short- or long-term detrimental effects in healthy people\n\nhttps://www.kcl.ac.uk/news/psilocybin-in-10mg-or-25mg-doses-has-no-short-or-long-term-detrimental-effects-in-healthy-people\n\nhttps://journals.sagepub.com/doi/full/10.1177/02698811211064720\n\nThe therapeutic potential of microdosing psychedelics in depression\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457631/\n\nMicro dose, 5% to 10% of psychotropic dose\n\nLSD (10\u201320\u2009mcg)\n\nPsilocybin (less than 1\u20133\u2009mg),\n\nhave subtle (positive) effects on cognitive processes (time perception, convergent and divergent thinking) and brain regions involved in affective processes.", "link": "https://www.youtube.com/watch?v=2LN6LJiXqWs", "date_published": "2022-08-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]